Message #56 From:
Stock News Bot Date: November 20, 2006 07:06:00 AM
MCET News MultiCell Technologies and SmallCapInsights.com Highlight CEOs Presenting at Wednesday's Anticipated ``Emerging Growth Forum''
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. [OTCBB:MCET],
along with SmallCapInsights.com, a leading investment newsletter
committed to discovering tomorrow's smallcap breakthroughs, has
highlighted the Management that are scheduled to present during the
highly anticipated “Emerging Growth Forum”
scheduled for Wednesday, November 22, 2006, at 12 noon Eastern.
“We have gathered an exceptional group of high
profile management that have a commanding understanding of not only
their emerging companies, but also are able to provide in-depth analysis
of their industries as a whole,” said Dr. John
Faessel, publisher of the widely read online financial news source, Jag
Notes, and keynote speaker for the “Emerging
Growth Forum.”
This live over-the-Internet video presentation employs a fast-moving,
highly informative format designed specifically for the smallcap and
microcap investor.
Executives to present during forum:
Bryan Chance, CEO of Titan Global Holdings, has led
telecommunications, technology, healthcare, pharmaceutical
manufacturing, distribution and other service-based companies. His
international successes include establishing manufacturing joint
ventures in South America and Asia and product distribution agreements
with distributors in South America. He has a strong background in
business plan development, cash flow analysis, financial modeling,
company and business unit acquisition or divestiture, IPOs, SEC
reporting, operational and financial turnarounds, product and service
marketing, strategic planning and rapid growth company leadership.
Philip S. Pesin, CEO of Auriga Laboratories, has been a member of
Auriga’s board since inception. He brings
extensive experience in establishing innovative companies in the
pharmaceutical and other industries. An attorney and certified public
accountant, Mr. Pesin is the founder of The Sorrento Financial Group,
LLC, a financial services company specializing in private equity
investment with a focus on financing innovative, high-growth companies.
Dr. Stephen M. Chang, CEO and Ph.D., MultiCell Technologies, has
served as a director of the Company since June 2004, became president
of the Company in February 2005, and was appointed chief executive
officer (CEO) in May 2006. Dr. Chang is also president of MCT Rhode
Island Corp. and Xenogenics Corporation, and president, chief
financial officer (CFO), treasurer, and director of MCTI, a
partially-owned subsidiary of the Company.
John Flock, President of Peace Arch Entertainment, is responsible for
overseeing all operations of the Company. He also serves as President
of Peace Arch LA, which focuses on the development, financing,
production and licensing of feature films for the US market. Mr. Flock
started his career as an entertainment attorney and then spent more
than a decade financing and producing independent films.
The Forum will last approximately 20 minutes. There is no need to
pre-register. To view the webcast, visit http://smallcapinsights.com
five or ten minutes prior to the start time and log on. The conference
is free of charge and open to all interested investors.
For those unable to view the initial webcast, the Forum will be archived
for replay at http://smallcapinsights.com.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company
committed to the development of breakthrough therapeutics based on a
portfolio of therapeutic candidates and patented drug development
technology. MultiCell’s drug development
program is focused on modulation of the immune system.
MultiCell’s therapeutic pipeline includes
drug candidates some of which are in various advanced stages of human
clinical trials. These therapies include:
MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125
completed a Phase II clinical trial and demonstrated significant
efficacy in reducing chronic fatigue in MS patients. There is no drug
specifically approved for the treatment of chronic fatigue in MS
patients anywhere in the world.
MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in
preclinical development for the treatment of relapsing-remitting MS,
targets disease specific autoaggressive T-cells that destroy the
myelin sheath of nerve cells. MCT-175 successfully ameliorated the
disease in animal models.
MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical
development, targets disease-specific autoaggressive T-cells that
destroy insulin producing cells in the pancreas. MCT-275 completely
reversed the type-1 diabetic phenotype and prolonged life in animal
models.
MCT-465 in an adjuvant therapy for the treatment of virus infection
and cancer. MCT-465 in preclinical studies successfully reduced
pulmonary influenza virus levels 1,000-fold in animal models, and has
demonstrated effectiveness in reducing virus levels of HIV and HCV in
animal models. MCT-465 in preclinical studies successfully eliminated
certain types of tumors in animal models.
The Company also holds unique cell-based technology for use in drug
discovery screening applications, and is a leading producer of the cell
lines needed by the biotechnology industry to develop new drugs and
therapeutics. For more information about MultiCell Technologies, please
visit http://www.multicelltech.com.
About SmallCapInsights.com
The editors and publishers of SmallCapInsights.com have decades of
direct experience both in the markets and in the newsletter genre as
well as being avid students of the sector. The Companies we illuminate
and represent are those we feel have the best chance of enhancing
portfolio returns as we take them from initial profile to ongoing
in-depth coverage. We aren't married to any space within the smallcap
sector, just to those ideas and strategies that will make our opinions
and observations a relevant starting point to your complete and ongoing
due diligence. The good, the bad and the bizarre -- and hopefully
profitable -- will populate our pieces. Our readers will first and
foremost be our priority. Every article will include a detailed
disclaimer. We are not analysts, but rather view our picks as an
investor might: questioning, commenting and delivering our best
opinions, be they pro or con. As well, in each piece we will highlight a
technical opinion, which, though it can never be definitive, will serve
to give readers a quick snapshot of our current T/A thoughts. For more
information, visit http://www.smallcapinsights.com.
Compensation Disclosures
Editorial is provided by SmallcapInsights.com ("Smallcap") to provide
readers with information on publicly traded companies which have
retained Smallcap to provide editorial commentary. Smallcap receives
compensation for those services from the company, which consists of cash
and/or securities of the company. Factual information is obtained from
public filings and other sources deemed to be reliable; however,
Smallcap takes no responsibility for verifying the accuracy of such
information and makes no representation that such information is
accurate or complete. Further, Smallcap and its employees and affiliates
may own, or may purchase and sell, securities of the companies profiled.
Smallcap undertakes no obligation to inform readers about the ownership
or trading activities of it or its employees or affiliates in the
securities of the profiled companies. As of September 11, 2006,
SmallcapInsights.com receives an aggregate of US$21,500 for six months
of editorial coverage.
Forward-Looking Statements
Certain of the statements in this release may be considered
forward-looking statements. Smallcap makes no representation and
provides no assurance or guaranty that such forward-looking statements
will be prove to be accurate. Statements of opinion and belief are those
of the authors and/or editors of this release, and are based solely upon
the information possessed by such authors and/or editors; no inference
should be drawn that such authors or editors have any special or greater
knowledge about the companies profiled or any particular expertise in
the industries or markets in which the profiled companies compete. The
reader should verify all claims and complete his own due diligence
before investing in any securities of profiled companies. Neither
Smallcap nor anyone involved in the publication of this editorial is a
registered investment adviser or broker/dealer. Smallcap makes no
recommendation that the purchase of securities of companies profiled in
this editorial is suitable or advisable for any person or that an
investment such securities will be profitable. In general, given the
nature of the companies profiled and the lack of an active trading
market for their securities, investing in such securities is highly
speculative and carries a high degree of risk. An investor in such
securities should be prepared and able to bear a loss of his or her
entire investment. Nothing in this editorial should be construed as an
offer or solicitation to buy or sell any securities of any profiled
company.
